Under Continuous Consideration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Under Continuous Consideration
Continuous manufacturing is increasingly noted as an important long-term objective for the pharmaceutical industry. PTE talks with Tim Freeman, Director of Operations at Freeman Technology, about some of the central issues involved in this transition, as well as the supporting role of relevant analytical technology.


Pharmaceutical Technology Europe
Volume 23, Issue 11

The reality is that the depth of information needed to engineer an optimal manufacturing solution is very similar whether an operation is in batch or continuous mode. Historically though, the industry has not invested in the knowledge gathering required to optimise production; in part because of the lack of relevant analytical tools and, arguably, because of the regulatory structure. Once a batch operation was fixed, there was little the operators could do to accommodate variability in incoming raw material because the scope for process development and/or process optimisation was limited.

So the current vision is a big one that will have major implications for process development. The aim is a transition from empirical batch to knowledgebased continuous processing; the commercialisation of processes that compensate for upstream variation rather than simply translating it through to the product, with responsive processing inside the design space rather than fixed manual operation according to instruction.

How are the pharmaceutical industry's analytical requirements changing as a result of increased emphasis on continuous manufacture?

There are two strands to the changing requirement for analysis. Firstly, the focus on efficient continuous production increases the demand for analytical instruments that provide process-relevant information. In the powder testing area, for example, many of the traditional techniques simply cannot meet this need and so newer methods are gaining popularity. Powder rheometry measures powder under conditions that simulate what the powder observes during manufacturing, quantifying powder properties that directly correlate with in-process behaviour; for example, performance in a tableting press, mixing efficiency, dispersion from a dry powder inhaler, rather than simply classifying a powder according to a somewhat arbitrary scale.

Beyond this, there is a need for analytical solutions that meet the new requirements for process monitoring and control—process analytical technology (PAT). Such solutions add considerable value during process development and at the pilot stage, as well as in largescale production.

The confluence of current trends in manufacturing has prompted the narrow definition of PAT as being based on real-time, on- or in-line technologies, but this is debatable. More efficient manufacture relies on pinpointing those parameters that need to be controlled and identifying the technology that can measure these. This could involve the more sensitive offline analysis of feeds prior to their introduction into the plant,the intelligent use of soft sensors, at-line systems and, of course, realtime in-process measurement (2). The key is to focus on the information requirement and then identify the analytical solution that best meets it.

References

1. H. Evans, Pharm. Technol. Eur. 22 (2), 42–44 (2010).

2. N. C. Chakrabarti, "Virtual sensors for advanced pharmaceutical control," http://www.pharmamanufacturing.com/, accessed Oct. 14, 2011.

For a recent article on academic and industry trends in continuous manufacturing, please visit http://PharmTech.com/continuousprogress


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here